Evidence map›Paper›PMID 26552985›Full record

ArticleAntimicrobial agents and chemotherapy2016

C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.

Ronald S Veazey, Udayan Chatterji, Michael Bobardt, Kasi E Russell-Lodrigue, Jian Li, Xiaolei Wang, Philippe A Gallay

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ronald S VeazeyTulane National Primate Research Center, Covington, Louisiana, USA.
Udayan ChatterjiDepartment of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Michael BobardtDepartment of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Kasi E Russell-LodrigueTulane National Primate Research Center, Covington, Louisiana, USA.
Jian LiTulane University School of School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Xiaolei WangTulane National Primate Research Center, Covington, Louisiana, USA.
Philippe A GallayDepartment of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, USA gallay@scripps.edu.
Tulane University · USScripps Research Institute · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Early Events in Mucosal SIV PathogenesisR01AI084793 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI VEAZEY, RONALD S. · 2009 to 2013
$3.9M
C5a as an Anti-HIV Microbicidal CandidateR01AI087470 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2010 to 2014
$2.3M
Anti-HIV Microbicidal PeptidesR33AI079782 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2011 to 2013
$1.6M
Anti-HIV Microbicidal PeptidesR21AI079782 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2009 to 2010
$903k
NIAID NIH HHS AI079782NIAID NIH HHS AI087470NIAID NIH HHS R01 AI084793NIAID NIH HHS R01 AI087470NIAID NIH HHS R21 AI079782NIAID NIH HHS R33 AI079782NIH HHS P51 OD011104
6 · The paper itself

Abstract

A safe and effective vaginal microbicide could decrease human immunodeficiency virus (HIV) transmission in women. Here, we evaluated the safety and microbicidal efficacy of a short amphipathic peptide, C5A, in a rhesus macaque model. We found that a vaginal application of C5A protects 89% of the macaques from a simian-human immunodeficiency virus (SHIV-162P3) challenge. We observed no signs of lesions or inflammation in animals vaginally treated with repeated C5A applications. With its noncellular cytotoxic activity and rare mechanism of action, C5A represents an attractive microbicidal candidate.

Indexed as

Administration, IntravaginalAmino Acid SequenceAnimalsAnti-HIV AgentsFemaleInterferon-gammaInterleukin-2Interleukin-6Interleukin-8Macaca mulattaModels, MolecularMolecular Sequence DataPeptidesProtein Structure, SecondaryProtein Structure, TertiarySimian Acquired Immunodeficiency SyndromeAnti-HIV AgentsInterferon-gammaInterleukin-2Interleukin-6Interleukin-8PeptidesViral Nonstructural Proteins

Identifiers

PMID26552985
PMCPMC4704173
OpenAlexW2212002830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.